Paclitaxel tocopheryl-based emulsion - Sorrento Therapeutics

Drug Profile

Paclitaxel tocopheryl-based emulsion - Sorrento Therapeutics

Alternative Names: IG 004; IG-002; paclitaxel TPGS-based emulsion; QW 8184; S 8184; Tocosol paclitaxel

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Sonus Pharmaceuticals
  • Developer Sorrento Therapeutics
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Tubulin modulators; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Bladder cancer; Breast cancer; Colorectal cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours

Most Recent Events

  • 23 Nov 2016 Discontinued - Preclinical for Solid tumours (New delivery system) in USA (IV) (Sorrento Therapeutics pipeline, November 2016)
  • 08 Apr 2014 Further analyses of adverse events data from a phase III trial in Breast cancer presented at the 105th Annual Meeting of the American Association for Cancer Research (AACR-2014)
  • 31 Dec 2013 Preclinical trials in Solid tumours (TPGS-based nanoparticle emulsion) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top